[Chronic kidney disease and chronic heart failure: impact on prognosis and choice of pathogenetic therapy].

E M Mezhonov O M Reitblat Y A Vyalkina A A Airapetian E V Oshchepkova Fail T Ageev Z N Blankova O N Svirida I S Prints Igor Zhirov Sergey Tereshchenko Sergey A Boytsov

Published in: Terapevticheskii arkhiv (2024)

occurs in every 3 patients with CHF across the entire range of LVEF. A decrease in GFR worsens the prognosis of patients with both HFrEF and HFpEF, increasing in direct proportion with the severity of the stage of CKD. Inclusion of patients in the monitoring program within the framework of the CHF service allows the treatment to be significantly brought closer to optimal drug therapy, at the same time, certain efforts are required to overcome difficulties with titration to target dosages.

Keyphrases

chronic kidney disease
end stage renal disease
ejection fraction
peritoneal dialysis
healthcare
newly diagnosed
mental health
prognostic factors
patient reported outcomes
bone marrow
replacement therapy
cell therapy
patient reported